In vitro studies have revealed that the v-mos-transformed clone mos2 (mos2) of the murine macrophage cell line P388D1 (D1) (H-2d) is capable of inducing a state of specific unresponsiveness in MHC-allogeneic unprimed T cells. Here, we present data on the in vivo relevance of these findings. Male C57bl/6 mice (H-2b) were injected i.p. 6 times with 10(7) of the following irradiated cell types: D1, mos3, mos2, DBA/2-(H-2d) or C3H-(H-2k) spleen macrophages. DBA/2 and C3H skin or heart grafts were performed 10 days after the last injection. The normal rejection time for allogeneic skin was 7.5 days and for allogeneic hearts, was 12.8 days. After injection of D1 or mos3, DBA/2 skin grafts were rejected after 4.5 and 6.5 days, respectively, and the hearts, after 15.4 and 18.6 days, respectively. Third-partly C3H grafts were rejected normally (7.0 days). In contrast, injection of mos2 led to prolongation of DBA skin graft survival to 12.3 days. DBA/2 hearts were accepted for more than 160 days as revealed by heart beating. Again, C3H grafts were rejected normally (11.0 days). DBA/2 skin grafts on day 102 after heart grafting survived for 30 days, indicating hyporesponsiveness against these grafts. These results confirmed the in vitro findings. The mos2 cells obviously induced a state of specific unresponsiveness in otherwise unmanipulated recipients. However, the duration of this unresponsiveness induced by the injection of irradiated cells was dependent on the organ type.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1432-2277.1994.tb01454.x | DOI Listing |
PLoS One
January 2025
Faculty of Veterinary Science, Veterinary Clinical Stem Cell and Bioengineering Research Unit, Chulalongkorn University, Bangkok, Thailand.
Potential trend of regenerative treatment for type I diabetes has been introduced for more than a decade. However, the technologies regarding insulin-producing cell (IPC) production and transplantation are still being developed. Here, we propose the potential IPC production protocol employing mouse gingival fibroblast-derived induced pluripotent stem cells (mGF-iPSCs) as a resource and the pre-clinical approved subcutaneous IPC transplantation platform for further clinical confirmation study.
View Article and Find Full Text PDFRadiographics
February 2025
From the Department of Radiology (S.Q., R.C., J.C.C., M.M., B.D.A., R.A.) and the Division of Cardiology, Department of Medicine (V.A., J.E.W., R.L.W., D.C.L.), Northwestern University Feinberg School of Medicine, 737 N Michigan Ave, Ste 1600, Chicago, IL 60611; Prince Charles Hospital, Chermside, Queensland, Australia (V.A.); and the Department of Biomedical Engineering, McCormick School of Engineering, Northwestern University, Chicago, Ill (M.M.).
Orthotopic heart transplant (OHT) is a well-established therapy for end-stage heart failure that leads to improved long-term survival rates, with careful allograft surveillance essential for optimizing clinical outcomes after OHT. Unfortunately, complications can arise after OHT that can compromise the success of the OHT. Cardiac MRI is continually evolving, with a range of advanced techniques that can be applied to evaluate allograft structure and function.
View Article and Find Full Text PDFPediatr Nephrol
January 2025
Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, 105-8461, Japan.
Patients with kidney failure require dialysis or kidney transplantation. Kidney transplantation offers great benefits, including reduced mortality; however, many patients who wish to undergo kidney transplantation are unable to do so due to a shortage of donor organs. This shortage is a global issue, and xenotransplantation has emerged as a potential solution.
View Article and Find Full Text PDFTransplantation
January 2025
Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA.
Curr Opin Organ Transplant
January 2025
Division of Nephrology, Virginia Commonwealth University, Richmond, Virginia, USA.
Purpose Of The Review: Calcineurin inhibitors (CNIs) are central to immunosuppression in kidney transplantation (KT), improving short-term outcomes but falling short in enhancing long-term outcomes due to cardiovascular, metabolic, and renal complications. Belatacept, an FDA-approved costimulation blocker, offers a less toxic alternative to CNIs but is limited by its intravenous administration and reduced efficacy in high-immunological-risk patients.
Recent Findings: Emerging therapies target more specific pathways to improve efficacy and accessibility.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!